Translational Session
New Directions and Strategies to Improve Hypertension and Pain Management in CKD
November 03, 2022 | 02:00 PM - 04:00 PM
Location: W415 Valencia, Orange County Convention Center, West Building
Session Description
Patients with CKD often have uncontrolled hypertension despite a plethora of antihypertensive agents. African Americans have a higher prevalence of uncontrolled hypertension. Patients with CKD can experience uncontrolled pain requiring opioids. This session focuses on new strategies for improving hypertension and opioid pain management in CKD. Presenters show the emerging role of genomic and pharmacogenomic testing for hypertension management in CKD and describe the implementation of pharmacogenomic testing for both hypertension management and pain control.
Learning Objective(s)
- Explain the emerging role of genomics and pharmacogenomics in hypertension management in CKD
- Discuss the feasibility and challenges of implementing genomic testing for hypertension management
- Determine the feasibility and challenges of implementing pharmacogenomic testing in clinical practice
- Describe evidence supporting the use of pharmacogenetics to guide opioid use and applications in the practice setting
Learning Pathway(s)
- CKD Non-Dialysis
- Pharmacology
Moderators
- Linda Awdishu, PharmD, FASN
- Adriana Hung, MD, MPH
Presentations
- It's in the Genes: The Knowns and Unknowns of Hypertension and CKD Progression in African American Patients
02:00 PM - 02:30 PM
Carol Horowitz, MD, MPH
- Implementation of a Genomics Program to Guide Optimal Selection of Antihypertensive Medications
02:30 PM - 03:00 PM
Rhonda M. Cooper-DeHoff, PharmD, MS
- Get Smart: Using Pharmacogenomics in CKD Hypertension Management
03:00 PM - 03:30 PM
Michael T. Eadon, MD, FASN
- Improving Effectiveness and Safety of Opioid Use Through Pharmacogenomics-Guided Therapy
03:30 PM - 04:00 PM
D. Max Smith, PharmD
